Table 1 Clinical and pathological data of morphologically normal prostatic tissue and prostate cancer patients submitted to a prostate biopsy (cohort #1) included in this study
(Cohort #1) | ||
|---|---|---|
Clinicopathological data | MNPT | PCa (biopsies) |
Patients, n | 15 | 74 |
Median age, years (range) | 64 (45–80) | 69 (51–85) |
Median PSA (ng/mL) (range) | n.a. | 18.22 (4.52–542.00) |
Clinical stage, n (%) | ||
II | n.a. | 48 (64.86) |
III | n.a. | 12 (16.22) |
IV | n.a. | 14 (18.92) |
Prognostic grade group, n (%) | ||
1 | n.a. | 30 (40.54) |
2 | n.a. | 17 (22.97) |
3 | n.a. | 16 (21.62) |
4 | n.a. | 7 (9.46) |
5 | n.a. | 4 (5.41) |
CAPRA score, n (%) | ||
Low risk (0–2) | n.a. | 7 (9.46) |
Intermediate risk (3–5) | n.a. | 26 (35.14) |
High risk (6–10) | n.a. | 41 (55.41) |
D’Amico risk classification, n (%) | ||
Low risk | 7 (9.46) | |
Intermediate risk | 23 (31.08) | |
High risk | 44 (59.46) | |
Treatment | ||
Radical prostatectomy/radiotherapy | 39 (52.70) | |
Hormonotherapy | 35 (47.30) | |
Follow-up | ||
Median (months, IQR) | n.a. | 104.04 (67.03–145.48) |
Patients without remission, n (%) | n.a. | 3 (4.05) |
Biochemical recurrence, n (%) | n.a. | 13 (33.33) |
Progression of disease, n (%) | n.a | 16 (45.71) |
Death due to PCa, n (%) | n.a. | 13 (17.57) |